complete remission (CR) rates (40-50%) with median overall survivals of 18-24 months and progression-free survivals (PFS) of 12-25% in patients with breast cancer We investigated the outcomes of patients with breast cancer undergoing induction chemotherapy, mobilizresponsive to conventional induction chemotherapy. 1-6 A recent randomized phase III trial demonstrated the superioration of peripheral blood stem cells (PBSC) and highdose chemotherapy (HDC) with PBSC infusion. One ity of two cycles of HDC with peripheral blood stem cell (PBSC) support compared to conventional-dose treatment hundred and fourteen patients with untreated stage IV breast cancer, with a median age of 46 years (range 24-in patients with newly diagnosed metastatic breast cancer.
Treatment centers Toxicity grading
Patients were treated in one of 24 participating medical cenAll patients were evaluated daily until resolution of signs ters in the United States under the care of 159 community and symptoms and graded for toxicity using standard oncologists. 8 Chemotherapy for all three phases of treatcriteria.
11 ment was administered and PBSC harvested in an outpatient facility. At the completion of PBSC infusion Evaluation of response patients were admitted to hospitals meeting the criteria of ASCO/ASH guidelines for stem cell transplantation. 9 Patients were staged prior to AFM induction, following AFM induction and 60 days following PBSC infusion. Staging included computed tomography (CT) scans of the Induction chemotherapy (AFM) chest, abdomen and brain, an isotopic bone scan and a bone All patients were scheduled to receive four courses of marrow aspirate and biopsy. induction chemotherapy at 14 day intervals consisting of:
Complete response was defined as complete clinical resdoxorubicin, 50 mg/m 2 , by continuous i.v. infusion over olution of all evidence of disease. Partial response (PR) was 24 h; methotrexate, 60 mg/m 2 , i.v. bolus on day 1; leucovodefined as 50% or greater reduction in the sum of the prorin 10 mg/m 2 orally q 6 h × 6 doses and 5-flurouracil 600 ducts of all measurable lesions and at least 50% improvemg/m 2 i.v. bolus on day 2. ment in tumor markers. Partial response* (PR*) was defined as complete clinical resolution of all evidence of non-skeletal disease with a bone scan showing improveMobilization chemotherapy (CEP) ment, with evidence of sclerosis of lytic lesions on X-ray Patients who completed AFM were scheduled to receive or CT and bone pain that had completely resolved. 1 For cyclophosphamide 4 g/m 2 on day 1 and etoposide 200 statistical purposes patients with PR and PR* were included mg/m 2 , cisplatin 35 mg/m 2 on days 1-3 (CEP) followed by together as PR. Patients were classified as no evident disfilgrastim 6 g/kg/day beginning on day 4 and continued ease (NED) if disease could not be detected after surgery until PBSC harvests were complete. 10 at the time of diagnosis of metastatic disease.
Collection, cryopreservation and infusion of PBSC
Statistics Peripheral blood stem cells were collected and cryopreData were collected using a custom designed distributed served as previously described. 8, 10 Attempts were made to data system, reviewed at a central clinical center (Response collect у2.5 × 10 6 CD34 + cells/kg from each patient. 8 Oncology, Inc., Memphis, TN, USA) and analyzed using Cryopreserved PBSC were thawed and infused 72 h after the SAS system (SAS Institute, Cary, NC, USA). Actuarial the last dose of chemotherapy. 10 The day of PBSC infusion probabilities were computed according to the methods of was designated day 0.
Kaplan and Meier 12 and compared using the log rank test.
13
The endpoints for survival were duration from enrollment High-dose chemotherapy until death censored by the date of last contact, and for relapse or progression from enrollment until relapse or proCyclophosphamide 2 g/m 2 /day, thiotepa 167 mg/m 2 /day gression censored by death or end of follow-up. The date and carboplatin 267 mg/m 2 /day were administered in 1 h of last follow-up was 1 May 1996. Multivariate analyses infusions for 3 consecutive days. All patients received filwere performed using a proportional hazards regression grastim 6 g/kg/s.c./day from the day of PBSC infusion model. 14 All proportions were compared using an adjusted (day 0) until the ANC was Ͼ0.5 × 10 9 /l for 3 consecutive 2 test. days. 5 The clinical factors evaluated, on an intent to treat basis for all 114 patients, for potential prognostic significance are Treatment after high-dose chemotherapy and PBSC shown in Table 4 . For the 68 patients with measurable disinfusion ease who completed all three phases of therapy, response to AFM (PR + PR* and/or CR vs all others) was added to Hormonal: Twenty-four patients who were estrogen recepthe model along with the factors listed in Table 4 . tor and/or progresterone receptor positive were given tamoxifen 10 mg, orally, twice a day or megace 40 mg, orally, four times a day following recovery from HDC for a minimum of 2 years or until disease progression.
Results
Radiation therapy: Local radiation therapy, 2.0-5.0 Gy, Patient characteristics was given after PBSC infusion and prior to disease pro- Tables 1 and 2 show the characteristics of the 114 patients gression to sites of previous disease involvement to 21 of enrolled on this trial. Twenty-nine patients were not evalu-99 patients receiving HDC and PBSC.
able for response; 10 were NED following surgery (three with supraclavicular node, one with axillary node, two with Chemotherapy: One patient was treated with 5-flurouracil beginning immediately after hematological recovery folchest wall, three with lung and one with ovarian involvement) and 19 had bone-only disease. As a generality lowing CTCb to the present time. + cells/kg (range 1.77-69.43) the fourth course of AFM, 2.5 months after enrollment. The median time to administer AFM to these 114 patients was was infused on day 0. The median days to recovery of an ANC Ͼ0.5 × 10 9 /l and platelets to Ͼ20 × 10 9 /l were 10 83 days (range 61-125).
(range 7-19) and 10 (range 5-25), respectively. The median numbers of platelet and red blood cell transfusions adminisResponse to AFM: Eighty-five patients with measurable tered were 3 (range 0-14) and 1 (range 0-4), respectively. disease were treated with AFM; 7/85 (8%) had progressive disease, 29/85 (34%) had stable disease, 29/85 (34%) achieved PR and 20/85 (24%) achieved CR. Among the 39
Intent to treat analyses patients who had lung and/or liver involvement four (10%)
Response: Thirty-eight of 85 patients with measurable disachieved CR and 11 PR (28%). Among the 18 patients who ease achieved CR (45%) and 20 achieved PR (24%) for an had failed doxorubicin adjuvant therapy three achieved CR overall response rate of 69%. (17%) and six PR (33%). One of 37 patients with bone plus other involvement achieved PR*.
Survival and progression-free survival: Fifty-two patients (46%) are alive, 21 progression free (18%), with a median Mobilization of PBSC with CEP and filgrastim survival of 31 months (range 22-47). The probabilities of survival and PFS at 3.5 years for all 114 patients are 0.40 One hundred and seven patients (94%) received CEP and 0.17 respectively ( Figure 1 ). (Table 3) .
The interval from completion of AFM (last dose of Univariate and multivariate analyses: Table 4 shows the doxorubicin) to the initiation of CEP for the 107 patients variables entered into univariate analyses with survival and treated was 34 days (range 14-74) and all received the PFS as outcome endpoints. Patients with lung and/or liver planned doses of drugs. Forty-four patients (39%) were metastasis, a history of doxorubicin adjuvant therapy, hospitalized for a median of 7 days (range 3-17).
detectable disease and more than five lesions in the dominant organ at diagnosis were at increased risk for proNon-hematological toxicities of CEP: The major nongression or relapse. Eighty-two patients were ER+ and/or hematological grade 3-4 toxicities of CEP included: fever PR+ or unknown; 32 were hormone refractory and they had (46.1%), nausea and/or vomiting (25%), pulmonary coma median PFS of 16.6 months as compared to a PFS of plications (13%), stomatitis (10%) and diarrhea (6%).
13.2 months for 52 patients who were not hormone refractory; 30 patients were ER/PR negative and they had a Hematological toxicities of CEP: All patients experienced median PFS of 11.1 months (P = 0.92). grade 3-4 neutropenia and thrombocytopenia. The median
In the multivariate analysis patients with lung and/or duration of an ANC Ͻ0.5 × 10 9 /l and platelets Ͻ20 × 10 9 /l was 7 (range 0-14) days and 2 (range 0-10) days, respectively. A median of 1 red blood cell (range 0-5) and 2 (range 0-10) platelet transfusions were administered, respectively.
Collection of peripheral blood stem cells following CEP:
Peripheral blood stem cells were harvested from 105 of 107 patients who received CEP. Two patients did not have PBSC collected after CEP because of refusal or refractory thrombocytopenia. The median number of CD34 + cells collected was 11.18 × 10 6 /kg (range 0.14-138.85) in a median of 2.5 apheresis procedures (range 1-9).
High-dose chemotherapy with CTCb followed by PBSC infusion
Ninety-three patients (82%) received all the planned doses of CTCb as per protocol (Table 3 ). The interval from the administration of CEP to initiation of CTCb was 37 days talized for a median of 10 days (range 0-25). liver involvement were 2.5 times more likely to relapse or progress and patients who had received prior adjuvant therapy with doxorubicin were 2.0 times more likely to relapse or progress than patients without these risk factors (Table  5 ). All 39 patients with lung and/or liver involvement and all 23 patients who had failed doxorubicin adjuvant therapy have progressed (Figures 2 and 3) .
Outcomes for 93 patients completing the protocol
One of 93 patients died in the first 100 days of PBSC infusion; from complications of progressive disease on day 16. The probabilities of survival and PFS at 3.5 years for the Table 5 Multivariate correlates of mortality or progression intent to treat analysis (n = 114) 
Outcome for all patients receiving high-dose chemotherapy
The outcomes for the 99 patients who ultimately received HDC and PBSC infusion are shown in Figure 4 . Ninetythree patients received CTCb as per protocol, five received CTCb off protocol and one received busulfan, melphalan and thiotepa prior to PBSC infusion (Table 3) .
Outcome for patients not completing the protocol
Three of 15 patients (20%) not receiving HDC are alive, bocytopenia after CEP is in CR at 33 months (Table 3) .
Five of six patients receiving HDC off protocol are alive 26-34 months after diagnosis; one progression-free, while four are alive after disease progression. 93 patients completing all three phases of the protocol were 0.42 and 0.19, respectively.
Sixty-eight patients with measurable disease received Characteristics of patients surviving without progression CTCb and PBSC infusions as per protocol. Table 6 summa- (Table 7 ) rizes the responses observed in relation to the initial Twenty-one patients survive without disease progression; response to AFM. Seven of 27 patients (26%) with lung 20/99 (20%) who received HDC with PBSC infusion and and/or liver metastasis achieved CR and eight (30%) PR 1/15 (7%) who did not. (PR* = 3) following CEP and CTCb. Five of 13 patients (39%) with a history of prior doxorubicin adjuvant achieved CR and 3/13 (23%) achieved PR*. The 35 patients Discussion without either risk factor had a CR rate of 60% and a PR rate of 23%.
The current study was designed to determine the outcome Multivariate analysis involving the 68 patients with of patients with stage IV breast cancer committed at diagmeasurable disease, including response as a covariable, nosis to receive induction chemotherapy, mobilization demonstrated that patients with a history of prior doxorubchemotherapy and HDC with PBSC infusion. This strategy icin adjuvant therapy had a 2.4-fold and patients with lung and/or liver involvement had 2.5-fold probability of relapse or progression (P = 0.009 and 0.001, respectively).
Patients who responded to AFM had a better PFS (9/43) than patients who did not respond (1/25, P = 0.06). In the multivariate analysis, response to AFM (PR + PR* and/or CR vs all others) was not a statistically significant predictor of outcome (P = 0.10).
Four of the 15 patients (27%) who were not in CR after AFM but achieved CR after CEP and CTCb are surviving without disease progression. The probabilities of survival and PFS, at 3.5 years, for the patients with measurable disease who were in CR after CEP and CTCb were 0.37 and Table 6 Response in patients with measurable disease completing the protocol (n = 68) who had ϽPR following AFM (JJ). obviously does not completely prevent bias as physicians an ultimate CR rate of 45% with one treatment-related death and a PFS of 17% at 3.5 years. The PFS of 19% participating in this study could treat selected patients with less intensive therapy rather than enroll them on this more following CTCb and PBSC infusion is similar to that reported in other studies using the same or comparable intensive protocol. Patients could also elect to receive conventional-dose chemotherapy. Nevertheless, this study treatment regimens. [1] [2] [3] [4] 6 In multivariate analyses, patients with a history of prior demonstrated that 82% of patients who consented and were enrolled completed all three phases of the planned therapy doxorubicin adjuvant therapy had a 2.0-fold and patients with lung and/or liver involvement had a 2.5-fold increase with one infectious death after AFM, manageable morbidity and failure almost exclusively related to disease proin the risk of relapse or progression. In addition, the small group of patients who entered the trial NED following surgression.
There were seven protocol violations (6%) in this study; gery had a significantly improved outcome with 6/10 patiens alive and disease-free 25 to Ͼ40 months after diagfive due to the administration of paclitaxel by the treating physician prior to CTCb, one due to the administration of nosis. Although patients with only one site of disease had a better survival in univariate analyses this effect was not a more aggressive treatment regimen before PBSC infusion and one due to the omission of CEP. Thus, the majority of seen in multivariate analyses. No other pre-treatment risk factors affecting PFS could be identified. All survivors were violations were due to the administration of more rather than less therapy.
NED, had bone-only disease, had local soft-tissue, axillary nodal or supraclavicular nodal disease, with or without Eight patients (7%) did not complete the protocol because of progressive disease following AFM (n = 4) or a bone disease, at the time of diagnosis. Hormonal status at diagnosis had no impact on outcome. poor response to CEP (n = 4). Two additional patients had progressive disease after AFM but could not have pro-ER+ and/or PR+ patients who were hormone refractory had equivalent survival to patients who were ER+ and/or PR+ ceeded to CEP due to infectious death in one and cardiac complications in another. Although not an absolute contraand not refractory or to patients who were ER/PR negative. Since tamoxifen or megace were given to only 24 patients indication, patients with progressive disease or poor response to AFM and CEP were generally taken off study after HDC we were unable to determine the impact of hormonal therapy on outcome. Future studies which closely because of the relatively poor results of high-dose CTCb in patients with refractory breast cancer. 1, 5, 6 Only three monitor compliance of hormone administration will need to be carried out to clarify this issue. patients with progressive disease following AFM proceeded to HDC and all progressed following CTCb.
In this and in a previous analysis patients with a history of doxorubicin adjuvant therapy were less likely to achieve Analyzed on an intent to treat basis, patients with newly diagnosed metastatic breast cancer in the current study had long-term PFS following HDC than patients receiving non-doxorubicin containing adjuvant or no adjuvant therapy. 5 suggesting that complete disappearance of tumor prior to In the current study all 23 patients who had received HDC is not an absolute prerequisite to tumor eradication doxorubicin adjuvant therapy relapsed or progressed by 24 in some patients. However, since re-staging was not performonths from diagnosis of metastatic disease (Figure 2) . med after CEP some stable or PR patients after AFM could Other investigators have observed a negative effect of prior have been converted to CR prior to CTCb administration. adjuvant therapy on the results of chemotherapy at both
Since only 50-60% of patients with metastatic breast conventional, 17,18 and high doses. 1, 3, 19 Thirteen of 62 cancer achieve CR, PR involvement in induction strategies patients with advanced breast cancer who had received may improve the fraction of patients who benefit from HDC CTCb followed by autologous bone marrow were alive and and PBSC infusion for consolidation therapy. Noncrossdisease-free at 24-66 months and two had received doxoruresistant agents such as paclitaxel 22, 23 or docetaxel 24.25 bicin adjuvant therapy. 6 Without distinguishing between might play a useful role during induction therapy, doxorubicin and non-doxorubicin based therapy, Williams especially in patients who have failed doxorubicin adjuvant et al 3 found that patients who had received adjuvant chemotherapy. Studies to evaluate the outcome of patients receivtherapy were less likely to have prolonged PFS following ing HDC preceded by induction therapy with paclitaxel and HDC than patients not receiving adjuvant chemotherapy. mobilization of PBSC with cyclophosphamide and paclitNone of the four long-term survivors in the HDC trial of axel are currently being carried out. 26 Peters et al 4 had received adjuvant doxorubicin therapy. Treatment strategies associated with prolongation of conThe response rate to AFM in the 18 evaluable patients ventional-dose chemotherapy could be counterproductive, who had received doxorubicin adjuvant (PR + CR) was however. Although induction chemotherapy may produce 50% which was not remarkably different than for the 67% initial responses, resistant clones can develop with extended for patients not receiving doxorubicin adjuvant therapy.
conventional dosing making it difficult for HDC to eradiFollowing CTCb 5/13 (39%) evaluable patients who had cate minimal residual tumor. 27 Instead of conventional-dose received prior doxorubicin adjuvant therapy were in CR but induction chemotherapy it might be advantageous to proall have progressed.
ceed directly at diagnosis to mobilization chemotherapy folNo patient with liver and/or lung involvement is survivlowed by HDC and PBSC infusion. Alternatively, induction ing progression-free (Figure 3 ). Long-term survival of could be carried out with more intensive cycles of chemopatients with visceral dominant metastatic disease followtherapy with or without PBSC support. 28, 29 ing conventional-dose chemotherapy has also been More intensive HDC regimens prior to PBSC infusion unusual. 19 Liver disease predicted for a shorter survival folmight achieve more meaningful tumor log kill in patients lowing HDC with two cycles of CEP. 20 However, visceral with unfavorable disease. Fields et al 30 have reported involvement was present in 6/13 long-term survivors folencouraging results in patients receiving ifosfamide, carbolowing high-dose CTCb and bone marrow infusion in one platin and etoposide pushed to the limit of clinical tolerstudy where the number of sites rather than specific sites ance. A regimen of high-dose busulfan, melphalan and thiof metastatic disease was the strongest predictor of treatotepa has been explored in phase I and II studies in patients ment failure. 6 with poor-risk stage IV breast cancer with encouraging The lack of survivors among patients with visceral disresults. 15, 16 ease is disappointing and may, in part, be due to initial Non-hematological dose-limiting toxicity has been induction failure as only 10% of these patients achieved a reached with many alkylating agent-based HDC regimens. CR to AFM and only 26% were in CR after CEP and This has prompted the evaluation of tandem HDC strategies CTCb.
to decrease toxicity and improve the therapeutic index. The Response to chemotherapy has been identified as a major feasibility of tandem HDC treatments followed by bone factor predictive of outcome in all previous studies. [1] [2] [3] [4] 21 marrow infusion in patients with advanced breast cancer Ayash et al 6 reported that chemosensitive disease, minimal has been demonstrated. 21, 31 In the majority of patients an tumor bulk and a prolonged disease-free interval from excess of PBSC can be collected with the initial aphereses initial diagnosis to metastatic disease were independently making tandem HDC treatments in patients with breast canassociated with improved disease-free survival after CTCb.
cer more practical. 8, [32] [33] [34] [35] [36] [37] Given the heterogeneity of the Thirty-one percent of patients in that study, however, had patient populations treated it is impossible to reach any confailed chemotherapy for metastatic disease and received clusions about the relative efficacy of tandem HDC. The reinduction therapy prior to CTCb while in the present strategy appears to be feasible in the majority of patients study only initial response to treatment was evaluated.
with metastatic breast cancer and warrants further investiIn the current study, 68 patients with measurable disease gation. completed all three phases of the protocol. Patients who An alternative to tandem HDC treatments with a relaresponded to AFM had a better PFS (9/43) than patients tively long interval in between is to rapidly sequence (every who did not respond (1/25). In the multivariate analysis, 2 weeks) intermediate-dose therapy. This has been however, response to AFM was not a statistically signifiaccomplished with growth factor 29 or PBSC support after cant predictor of outcome (P = 0.10). Thus, visceral each course. 28 Norton 38 has postulated that rapid sequeninvolvement and a history of doxorubicin adjuvant therapy cing of dose-intensive therapy may overcome drug resistwere more important risk factors for failure than response ance. It remains to be determined, however, whether this to induction therapy. approach offers any advantage over a single HDC treatment Although the numbers are small, patients with PR or CR to AFM had equivalent PFS following CTCb (Figure 4) for patients with metastatic breast cancer. Nevertheless, it 
